Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 13/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.33 |
| ▸ | FEN1 | P39748 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12017977 | 1.00 | MMP2 (0.40) | MMP2MMP13HCRTR2POLBCA1 | |
| SCHEMBL12017953 | 1.00 | MMP2 (0.40) | MMP2MMP13HCRTR2POLBCA1 | |
| SCHEMBL12017966 | 1.00 | MMP2 (0.40) | MMP2MMP13HCRTR2POLBCA1 | |
| SCHEMBL12018129 | 0.96 | MMP2 (0.43) | MMP2MMP13HCRTR2POLBNPSR1 | |
| SCHEMBL12017976 | 0.96 | MMP2 (0.43) | MMP2MMP13HCRTR2POLBNPSR1 | |
| SCHEMBL4836163 | 0.84 | POLB (0.41) | HCRTR2POLBCA1CA2NPSR1 | |
| SCHEMBL4836161 | 0.84 | POLB (0.41) | HCRTR2POLBCA1CA2NPSR1 | |
| SCHEMBL4836171 | 0.84 | POLB (0.41) | HCRTR2POLBCA1CA2NPSR1 | |
| SCHEMBL6242863 | 0.78 | GRIA4 (0.47) | MMP2MMP13HCRTR2CA1CA2 | |
| SCHEMBL13979527 | 0.76 | APLNR (0.32) | HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3821947-A1 | HETEROCYCLIC TRPML1 AGONISTS | Libra Therapeutics, Inc. (US) | 2021-05-19 | — | — | EP | disclosed |
| US-8263585-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| US-8263585-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| EP-2173722-B1 | PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2012-08-29 | — | — | EP | disclosed |
| US-20090163463-A1 | Organic Compounds | NOVARTIS AG | 2009-06-25 | — | — | US | disclosed |
| US-20090163463-A1 | Organic Compounds | NOVARTIS AG | 2009-06-25 | — | — | US | disclosed |
| WO-2009013348-A2 | PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2009-01-29 | — | — | WO | disclosed |
| US-7285368-B2 | Polymerizable ester having sulfonamide structure, polymer, resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-20050003303-A1 | Polymerizable ester having sulfonamide structure, polymer, resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163463-A1 | Organic Compounds | PIK3C3, PIK3CA, MTOR | MMP2 2332/4885MMP13 1448/4885HCRTR2 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.